Akari TX

NEW YORK and LONDON, November 10, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA 

NEW YORK and LONDON, November 9, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

• Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials …

[Read more...] about Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

NEW YORK and LONDON, October 31, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …

[Read more...] about Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference